{
  "nctId": "NCT02485964",
  "briefTitle": "A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine",
  "officialTitle": "A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine",
  "protocolDocument": {
    "nctId": "NCT02485964",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2015-09-22",
    "uploadDate": "2021-08-12T17:00",
    "size": 183645,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02485964/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-08",
    "completionDate": "2018-12",
    "primaryCompletionDate": "2018-12",
    "firstSubmitDate": "2015-06-26",
    "firstPostDate": "2015-06-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Histological documented diagnosis of prostate cancer\n* 18 years of age or older\n* Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)\n\nExclusion Criteria:\n\n* Subjects must have no other current malignancies.\n* Subjects with prior history at any time of any basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration.\n* Subjects with other malignancies are eligible if they have been continuously disease free for â‰¥ 5 years prior to the time of registration",
    "healthyVolunteers": false,
    "sex": "MALE",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay",
        "description": "The spots formed by interferon-gamma-secreting T-cells will be counted with an automated ELISPOT analyzer (AID ELISPOT Classic Reader; Autoimmune Diagnostika GmbH, Strassberg, Germany). The average spot-forming units (SFU) per antigen will be calculated. A response will be considered positive when the average SFU in wells with a given peptide was at least twice that of the average SFU in the no-peptide control wells.",
        "timeFrame": "At time of consent"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 14,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-21T22:34:05.015Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}